Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Side-effects of intravenous immune globulins.

Literature DB >> 8033440

Side-effects of intravenous immune globulins.

Abstract

Intravenous immune globulin (IVIG) preparations are efficacious and safe products in use world-wide. Although rare, side-effects of IVIG may be serious, even life-threatening, and clinicians should be aware of their potential occurrence. This article summarizes most of the adverse experiences with IVIG reported in the literature since its introduction into clinical practice almost 15 years ago.

Mesh：

Substances：

Year: 1994 PMID： 8033440 PMCID： PMC1550378

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

36 in total

1. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

Authors: A W Burks; H A Sampson; R H Buckley
Journal: N Engl J Med Date: 1986-02-27 Impact factor: 91.245

2. Effect of intravenous immunoglobulin in immune thrombocytopenia.

Authors: A Salama; C Mueller-Eckhardt; V Kiefel
Journal: Lancet Date: 1983-07-23 Impact factor: 79.321

3. Alopecia after immunoglobulin infusion.

Authors: D Chan-Lam; E J Fitzsimons; W S Douglas
Journal: Lancet Date: 1987-06-20 Impact factor: 79.321

4. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients.

Authors: R K Woodruff; A P Grigg; F C Firkin; I L Smith
Journal: Lancet Date: 1986-07-26 Impact factor: 79.321

5. Non-A, non-B hepatitis after intravenous gammaglobulin.

Authors: O Weiland; L Mattsson; H Glaumann
Journal: Lancet Date: 1986-04-26 Impact factor: 79.321

6. Thrombotic events after intravenous immunoglobulin.

Authors: W D Frame; R J Crawford
Journal: Lancet Date: 1986-08-23 Impact factor: 79.321

7. Coronary revascularisation by percutaneous transluminal coronary angioplasty for recurrent ischaemic pulmonary oedema.

Authors: M Mosseri; Y Hasin; M S Gotsman
Journal: Lancet Date: 1986-10-25 Impact factor: 79.321

8. Immunologically active proteins in intravenous immunoglobulin.

Authors: L Lam; C F Whitsett; J M McNicholl; T W Hodge; J Hooper
Journal: Lancet Date: 1993-09-11 Impact factor: 79.321

9. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin.

Authors: J C Barton; G A Herrera; J H Galla; L F Bertoli; J Work; W J Koopman
Journal: Am J Med Date: 1987-03-23 Impact factor: 4.965

10. Hemolytic anemia following intravenous gamma globulin administration.

Authors: A G Brox; D Cournoyer; M Sternbach; G Spurll
Journal: Am J Med Date: 1987-03-23 Impact factor: 4.965

24 in total

Review 1. Management of rheumatic diseases in children.

Authors: B H Athreya
Journal: Indian J Pediatr Date: 1996 May-Jun Impact factor: 1.967

Review 2. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.

Authors: R Gottstein; R W I Cooke
Journal: Arch Dis Child Fetal Neonatal Ed Date: 2003-01 Impact factor: 5.747

3. Increased risk of adverse events when changing intravenous immunoglobulin preparations.

Authors: R Ameratunga; J Sinclair; J Kolbe
Journal: Clin Exp Immunol Date: 2004-04 Impact factor: 4.330

Review 4. Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors: Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal: Neurotherapeutics Date: 2012-01 Impact factor: 7.620

5. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.

Authors: Isabella Quinti; Annarosa Soresina; Carlo Agostini; Giuseppe Spadaro; Andrea Matucci; Ifigeneia Sfika; Helene Martini; Federica Borghese; Andrea Guerra; Vultaggio Alessandra; Marcella Visentini; Alessandro Plebani; Massimo Fiorilli
Journal: J Clin Immunol Date: 2008-05 Impact factor: 8.317

6. Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion.

Authors: Meir Mizrahi; Tomer Adar; Efrat Orenbuch-Harroch; Yair Elitzur
Journal: Case Rep Med Date: 2010-02-22

Review 7. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors: Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal: Cochrane Database Syst Rev Date: 2017-01-13

8. Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.

Authors: Bruno Ghirotto Nunes; Flávio Vieira Loures; Heloisa Maria Siqueira Bueno; Erica Baroni Cangussu; Ernesto Goulart; Giuliana Castello Coatti; Elia Garcia Caldini; Antonio Condino-Neto; Mayana Zatz
Journal: Eur J Hum Genet Date: 2017-10-27 Impact factor: 4.246

9. Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors: Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal: J Thromb Thrombolysis Date: 2014 Impact factor: 2.300

Review 10. Recurrent miscarriage.

Authors: Kirsten Duckitt; Aysha Qureshi
Journal: BMJ Clin Evid Date: 2008-04-14